Matinas BioPharma

$0.6692
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0009 (-0.13%) Today
$0.00 (0.00%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell MTNB and other stocks, options, ETFs, and crypto commission-free!

About MTNB

Matinas BioPharma Holdings, Inc., also called Matinas BioPharma, is a clinical-stage biopharmaceutical company, which focuses on enabling the delivery of life-changing medicines using its LNC platform technology. The company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins, and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. Read More Its anti-fungal product candidate, MAT2203, delivers broad-spectrum fungicidal agent, amphotericin B; and is being developed to prevent invasive fungal infections in patients with acute lymphoblastic leukemia. The company was founded in May 2013 and is headquartered in Bedminster, NJ.

Employees
15
Headquarters
Bedminster, New Jersey
Founded
2013
Market Cap
108.68M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
332.83K
High Today
$0.69
Low Today
$0.6451
Open Price
$0.69
Volume
498.80K
52 Week High
$1.50
52 Week Low
$0.40

Collections

MTNB Earnings

-$0.05
-$0.04
-$0.04
-$0.03
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected Nov 11, Pre-Market

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.